WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, has announced results of a new peer-reviewed study involving the ARROW® PICC with Chlorag+ard® Technology, published in the Fall 2014 issue of the Journal of the Association for Vascular Access (JAVA). The ARROW® PICC with Chlorag+ard® Technology is the world’s first and only antimicrobial and antithrombogenic PICC.
The research, using the ARROW® PICC with Chlorag+ard® Technology, determined that this kind of Peripherally Inserted Central Catheter (PICC) was associated with a nearly nine-fold drop in the rate of Central Line-Associated Bloodstream Infections (CLABSIs). The peer-reviewed study was conducted at Sharp Chula Vista Medical Center (SCVMC) in Chula Vista, Calif.
Hey, check out all the research scientist jobs. Post your resume today!
